|
JPH0757213A
(ja)
*
|
1993-08-13 |
1995-03-03 |
Matsushita Electric Ind Co Ltd |
磁気ヘッド
|
|
US6183744B1
(en)
*
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
EP1194167B1
(en)
*
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
|
ATE477276T1
(de)
*
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
US20160279239A1
(en)
*
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
JP5695287B2
(ja)
|
2002-10-02 |
2015-04-01 |
カリフォルニア インスティテュート オブ テクノロジー |
微小流体の核酸解析
|
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
CA2508831C
(en)
|
2002-12-13 |
2012-05-01 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
|
CN1767860A
(zh)
*
|
2003-01-31 |
2006-05-03 |
免疫医疗公司 |
施用治疗和诊断剂的方法和组合物
|
|
KR100930353B1
(ko)
*
|
2003-03-06 |
2009-12-08 |
엘지전자 주식회사 |
디스크 플레이어의 접속요청 처리방법
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
|
MXPA06004199A
(es)
*
|
2003-10-17 |
2006-06-28 |
Novo Nordisk As |
Terapia en combinacion.
|
|
NZ596984A
(en)
*
|
2003-11-17 |
2013-10-25 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US7589063B2
(en)
|
2004-12-14 |
2009-09-15 |
Aplagen Gmbh |
Molecules which promote hematopoiesis
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
CA2599734C
(en)
|
2005-03-03 |
2014-01-28 |
Immunomedics, Inc. |
Humanized l243 antibodies
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
JP2006248978A
(ja)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
*
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
JP5129122B2
(ja)
|
2005-04-26 |
2013-01-23 |
トリオン ファーマ ゲーエムベーハー |
癌治療のための抗体およびグルココルチコイドの組み合わせ
|
|
KR101446989B1
(ko)
*
|
2005-05-06 |
2014-10-15 |
지모제넥틱스, 인코포레이티드 |
Ｉｌ-31 단클론성 항체 및 사용법
|
|
SG170086A1
(en)
*
|
2006-03-09 |
2011-04-29 |
Aplagen Gmbh De |
Modified molecules which promote hematopoiesis
|
|
CL2007001536A1
(es)
|
2006-05-30 |
2008-01-25 |
Genentech Inc |
Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
|
|
BRPI0717902A2
(pt)
|
2006-12-01 |
2013-10-29 |
Medarex Inc |
"anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
AU2008211199A1
(en)
*
|
2007-01-26 |
2008-08-07 |
The Regents Of The University Of Colorado |
Methods of modulating immune function
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
US8957031B2
(en)
|
2007-10-23 |
2015-02-17 |
Regents Of The University Of Colorado, A Body Corporate |
Competitive inhibitors of invariant chain expression and/or ectopic clip binding
|
|
EP2237684A2
(en)
|
2008-01-08 |
2010-10-13 |
Akthelia Pharmaceuticals |
Agonists for antimicrobial peptide systems
|
|
FI3056514T4
(fi)
|
2008-01-15 |
2025-10-06 |
Univ Leland Stanford Junior |
Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
|
|
US11072655B2
(en)
|
2008-01-15 |
2021-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
PL4160212T3
(pl)
|
2008-01-15 |
2024-08-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markery komórek macierzystych ostrej białaczki szpikowej
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
US20110044988A1
(en)
*
|
2008-03-20 |
2011-02-24 |
Carolus Therpeutics, Inc. |
Methods of treatment using anti-mif antibodies
|
|
US20110070184A1
(en)
*
|
2008-03-24 |
2011-03-24 |
Carolus Therpeutics, Inc. |
Methods and compositions for treating atherosclerosis and related condidtions
|
|
CA2734265C
(en)
*
|
2008-08-20 |
2017-12-19 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
US20100183598A1
(en)
*
|
2008-11-12 |
2010-07-22 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
EP2198879A1
(en)
*
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
|
ES2738700T3
(es)
|
2009-02-13 |
2020-01-24 |
Immunomedics Inc |
Inmunoconjugados con un enlace escindible intracelularmente
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
MX2012003514A
(es)
*
|
2009-09-23 |
2012-04-19 |
Carolus Therapeutics Inc |
Metodos para tratamiento de inflamaciones.
|
|
WO2011056721A2
(en)
|
2009-11-05 |
2011-05-12 |
Center For Molecular Medicine And Immunology |
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
|
US20110243841A1
(en)
*
|
2010-04-01 |
2011-10-06 |
Immunomedics, Inc. |
Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
|
|
WO2011085354A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
|
DE102010026064A1
(de)
*
|
2010-06-30 |
2012-01-05 |
Siemens Aktiengesellschaft |
11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
|
|
DE102010026063A1
(de)
*
|
2010-06-30 |
2012-01-05 |
Siemens Aktiengesellschaft |
11C-markiertes Peptid zur Detektion eines krankhaften Gewebes
|
|
BR112013005116A2
(pt)
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
|
CA2860768A1
(en)
|
2011-01-05 |
2013-07-12 |
The Texas A&M University System |
Clip modulation for the treatment of mucosal diseases
|
|
ES2700514T3
(es)
*
|
2011-02-01 |
2019-02-18 |
Genmab As |
Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74
|
|
US8673308B2
(en)
*
|
2011-02-23 |
2014-03-18 |
Als Therapy Development Institute |
Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
|
|
CN103501825B
(zh)
|
2011-05-02 |
2017-03-15 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
|
WO2013012894A1
(en)
|
2011-07-18 |
2013-01-24 |
The Ohio State University |
Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
|
|
WO2013063186A2
(en)
|
2011-10-26 |
2013-05-02 |
Novartis Animal Health Us, Inc. |
Monoclonal antibodies and methods of use
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
WO2013085893A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
US9212224B2
(en)
*
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
CA2876706A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
GB201216649D0
(en)
*
|
2012-09-18 |
2012-10-31 |
Univ Birmingham |
Agents and methods
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
|
AU2013360335B2
(en)
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US20240139324A1
(en)
|
2012-12-13 |
2024-05-02 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
|
JP2016513098A
(ja)
|
2013-02-07 |
2016-05-12 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
|
|
WO2014127200A1
(en)
|
2013-02-15 |
2014-08-21 |
Immunomedics, Inc. |
Chimeric and humanized anti-histone antibodies
|
|
EP2774930A1
(en)
|
2013-03-07 |
2014-09-10 |
Aptenia S.R.L. |
Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
|
|
AU2014249243C1
(en)
|
2013-03-13 |
2019-08-08 |
Imaginab, Inc. |
Antigen binding constructs to CD8
|
|
EP2968585B1
(en)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN103207277B
(zh)
*
|
2013-03-28 |
2015-04-15 |
中国人民解放军第二军医大学 |
一种人源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
FI3677591T3
(fi)
|
2013-04-29 |
2023-04-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
WO2015067277A1
(en)
|
2013-11-07 |
2015-05-14 |
University Of Copenhagen |
Timp-1 binding partner
|
|
DK3424955T3
(da)
*
|
2013-12-25 |
2025-06-16 |
Daiichi Sankyo Co Ltd |
Fremgangsmåde til fremstilling af anti-trop2 antistof-lægemiddelkonjugat
|
|
KR20160113158A
(ko)
|
2014-01-27 |
2016-09-28 |
몰레큘러 템플레이츠, 인코퍼레이션. |
폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
|
|
EP3107577B1
(en)
|
2014-02-21 |
2024-03-20 |
IBC Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
|
EP3872090A1
(en)
*
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
KR102380402B1
(ko)
|
2014-04-03 |
2022-03-31 |
아이쥐엠 바이오사이언스 인코포레이티드 |
변형된 j-사슬
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
US10351621B2
(en)
|
2014-06-24 |
2019-07-16 |
Immunomedics, Inc. |
Anti-histone therapy in acute kidney injury
|
|
EP3191136A1
(en)
|
2014-09-08 |
2017-07-19 |
Michaela Arndt |
Construct for the delivery of a molecule into the cytoplasm of a cell
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN104280553B
(zh)
*
|
2014-09-22 |
2016-06-08 |
中国人民解放军第二军医大学 |
一种小鼠源性可溶型cd74蛋白的elisa检测试剂盒及检测方法
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
CA2961774C
(en)
|
2014-10-07 |
2023-05-23 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
RU2746021C2
(ru)
*
|
2015-02-18 |
2021-04-06 |
Ф.Хоффманн-Ля Рош Аг |
Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CN115093479A
(zh)
|
2015-03-04 |
2022-09-23 |
Igm生物科学股份有限公司 |
Cd20结合分子及其用途
|
|
EP4140492A1
(en)
|
2015-04-21 |
2023-03-01 |
Enlivex Therapeutics Rdo Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
US9797907B2
(en)
|
2015-04-22 |
2017-10-24 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
JP6771492B2
(ja)
|
2015-05-30 |
2020-10-21 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
GB201511191D0
(en)
*
|
2015-06-25 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
T-cell epitopes for the immunotherapy of myeloma
|
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
DK3355913T3
(da)
|
2015-09-30 |
2024-12-02 |
Igm Biosciences Inc |
Bindingsmolekyler med modificeret j-kæde
|
|
WO2017062271A2
(en)
|
2015-10-06 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody drug conjugate for anti-inflammatory applications
|
|
UY37030A
(es)
*
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
EP3407916B1
(en)
|
2016-01-29 |
2023-12-20 |
Merck Sharp & Dohme LLC |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
WO2017189279A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
|
CN109804246B
(zh)
*
|
2016-08-01 |
2022-05-17 |
健康研究公司 |
用于快速克隆t细胞受体的组合物和方法
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
JP7075134B2
(ja)
|
2016-12-07 |
2022-05-25 |
モレキュラー テンプレーツ，インク． |
部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
|
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
IL322309A
(en)
*
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
|
CN113164616A
(zh)
|
2018-09-26 |
2021-07-23 |
阿森迪斯药物股份有限公司 |
可降解的透明质酸水凝胶
|
|
CN111303293B
(zh)
*
|
2018-11-14 |
2022-08-30 |
杭州尚健生物技术有限公司 |
一种融合蛋白及其用途
|
|
PY2020118A
(es)
|
2019-05-20 |
2022-10-27 |
Servier Lab |
Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
|
|
BR112022009273A2
(pt)
|
2019-11-15 |
2022-10-04 |
Univ Tennessee Res Found |
Imunoglobulinas modificadas para direcionar depósitos amiloides
|
|
CN115427585A
(zh)
*
|
2020-02-20 |
2022-12-02 |
居里研究所 |
用于鉴定功能性疾病特异性调节性t细胞的方法
|
|
EP4178624A2
(en)
|
2020-07-07 |
2023-05-17 |
Bionecure Therapeutics, Inc. |
Maytansinoids as adc payloads and their use for the treatment of cancer
|
|
US20230181471A1
(en)
|
2020-07-09 |
2023-06-15 |
Hoffmann-La Roche Inc. |
Concentrated compositions of proteins, their preparation and use thereof
|
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
JPWO2022239720A1
(enExample)
|
2021-05-10 |
2022-11-17 |
|
|
|
CA3219124A1
(en)
|
2021-05-18 |
2022-11-24 |
University Of Tennessee Research Foundation |
Antibody-peptide fusion proteins for treating amyloid disorders
|
|
CN113238061B
(zh)
*
|
2021-07-09 |
2021-10-01 |
中南大学湘雅医院 |
以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
EP4385522A1
(en)
|
2021-08-13 |
2024-06-19 |
Kunshan Xinyunda Biotech Co., Ltd. |
Microtubule inhibitor-based antibody-drug conjugate
|
|
JP2024532295A
(ja)
|
2021-08-24 |
2024-09-05 |
クンシャン シンユンター バイオテック カンパニー，リミティド |
切断可能なリンカーを介して結合した抗体薬物複合体
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
KR20240099382A
(ko)
|
2021-11-03 |
2024-06-28 |
아피메트 게엠베하 |
이중특이적 cd16a 결합제
|
|
CN118401258A
(zh)
|
2021-12-09 |
2024-07-26 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
|
US20250387504A1
(en)
|
2022-05-20 |
2025-12-25 |
Novartis Ag |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
|
WO2024034684A1
(ja)
|
2022-08-10 |
2024-02-15 |
興和株式会社 |
新薬物複合体
|
|
CN116139267A
(zh)
*
|
2023-01-28 |
2023-05-23 |
华中科技大学同济医学院附属同济医院 |
小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用
|
|
WO2025220804A1
(ko)
*
|
2024-04-18 |
2025-10-23 |
주식회사 큐로셀 |
Cd5에 대한 신규 항체 및 이의 용도
|
|
WO2025250969A1
(en)
*
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|